About Us
Dr. Itay Perlstein
Dr. Itay Perlstein, Ph.D. graduated from the Hebrew University in Pharmaceutical Sciences in 2000 and perused his post doc in the University of Pennsylvania/TheChildren Hospital of Philadelphia in development of novelgene delivery systems. He then move to the Pharma industry where he served in the Clinical Pharmacology & Pharmacometrics departments of GSK (2004-2007), Merck (2007-2011), and BMS (2011-2015) with growing responsibilities as a Sr.PK/PD Scientist, a Study Director, and a Clinical Pharmacology Lead. He has an extensive experience in all clinical phases of drug development, from first-in-human tosuccessful global filing of blockbuster drugs: COREG CR ® (CHF, 2006), Benlysta® (Lupus, 2011), Belsomra® (insomnia, 2014), Eliquis® (anticoagulant, 2015), Uzedy® (Scizophrenia, 2023) . Throughout the years he gained broad experience in interactions withthe FDA, EMA, and major Health Authorities in the world. He has an established record of preparation and maintenance of regulatory documents and development plans. Dr. Perlstein is now providing independent consulting services for Pharma, Biotech, and Medical Device companies (directly or trough CROs).